LENZ Stock — LENZ Therapeutics Inc

LENZ Therapeutics Inc (LENZ)

Updated October 16, 2026.

LENZ is a Stock. Its deepest 1-year drawdown was 91.9%.

LENZ Therapeutics is a pharmaceutical company developing and commercializing therapies to improve vision, with product candidates including VIZZ and LNZ101 for treating presbyopia in adults. The company does not currently distribute dividends. It may appeal to growth-oriented investors seeking exposure to early-stage pharmaceutical development rather than income-focused investors.

LENZ performance

Returns are updating. LENZ's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 91.9%.

LENZ key facts

Asset type

Stock

Asset class

Equity

Inception date

06/25/2021

Distribution frequency

None

Last close

$3.27 (as of 2026-10-16)

Market cap

$102,744,522

Average volume

938849.0

Ex-dividend date

03/22/2024

Beta

1.73

Payout ratio

0.0%

EPS

$-4.13

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LENZ risks and drawbacks

The deepest 1-year drawdown on record here is 91.9%.

Who may consider LENZ — and who may not

It is a weaker fit for investors who need monthly cash flow (LENZ does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on LENZ

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions